BRAF and pleomorphic xanthoastrocytoma: The poor survival of the cohort, especially with grade 3 tumors, suggests the need for more aggressive treatment, including maximal resection followed by intensive adjuvant therapy and when possible, BRAF inhibitor therapy for V600E-positive PXA.